Clinical Trials Browser

Phase 1/2 × Recruiting × Etoposide × Clear all

NCT05019716 2026-03-18

Testing the Safety and Efficacy of the Addition of a New Anti-cancer Drug, ZEN003694, to Chemotherapy Treatment (Cisplatin and Etoposide or Carboplatin and Paclitaxel) for Adult and Pediatric Patients (12-17 Years) With NUT Carcinoma

Phase 1/2 Recruiting

Advanced NUT Carcinoma

NCT05384821 2026-03-18

MetroWilms

Phase 1/2 Recruiting

Kidney Neoplasms, Wilms Tumor

NCT05533775 2026-03-06

iMATRIX GLO

Phase 1/2 Recruiting

Recurrence

NCT07227597 2026-02-20

MK-6070-003

Phase 1/2 Recruiting

Small Cell Lung Cancer Extensive Stage

NCT02861573 2026-02-17

KEYNOTE-365

Phase 1/2 Recruiting

Metastatic Castration-Resistant Prostate Cancer

NCT06741644 2026-01-09

A Phase I/II Study of CS2009 in Participants With Advanced Solid Tumors

Phase 1/2 Recruiting

Other solid neoplasm

Advanced Solid Tumors

NCT06937866 2025-11-21

Maintenance Zanzalintinib With Etoposide After HDCT in GCT

Phase 1/2 Recruiting

Neoplasms, Germ Cell and Embryonal

NCT06030258 2025-04-30

IN10018 Combination Therapy in Treatment-naïve ES-SCLC

Phase 1/2 Recruiting

Small Cell Lung Cancer Extensive Stage

NCT06249191 2025-03-24

Mosunetuzumab With Chemotherapy for the Treatment of Patients With Untreated C-Myc Rearrangement Positive High Grade B Cell Lymphoma or Diffuse Large B Cell Lymphoma

Phase 1/2 Recruiting

Lymphoma, Large B-Cell, Diffuse

NCT06477523 2024-06-27

Phase 1b/2 Study of LDRT in Combination With AK104 Plus Chemotherapy as First-line Treatment for ES-SCLC

Phase 1/2 Recruiting

SCLC, Extensive Stage

NCT06372626 2024-06-14

Study of ZG005 in Combination With Etoposide and Cisplatin in Participants With Advanced Neuroendocrine Carcinoma.

Phase 1/2 Recruiting

Carcinoma, Neuroendocrine

NCT06217757 2024-05-13

Safety and Tolerability of LDRT+Sugemalimab+Chemotherapy+Olaparib for First-Line Treatment of SLFN-11 Positive ES-SCLC

Phase 1/2 Recruiting

Lung Neoplasms, Small Cell Lung Carcinoma